Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

被引:1
|
作者
Rakotoambinina, B
Médioni, J
Rabian, C
Jubault, V
Jais, JP
Viard, JP
机构
[1] Hop Necker Enfants Malad, Serv Immunol Clin, F-75743 Paris 15, France
[2] Hop Necker Enfants Malad, Dept Biostat, F-75743 Paris 15, France
关键词
lipodystrophy; protease inhibitors; nucleoside analogs; hyperlipidemia; HIV infection;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the frequency and features of lipodystrophic syndromes in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) with a protease inhibitor (PI), and examine whether clinical and biologic abnormalities are always associated in these conditions. Methods: Retrospective-prospective single-center observational study of 175 patients. Comparisons for continuous variables by t-test and paired t-test, and Kaplan-Meier analysis of time to onset of lipodystrophy were performed. Results: In all, 51 patients (29%) had morphologic changes, after a mean HAART duration of 20.0 +/- 6.1 months, and were categorized into pure lipoatrophy (n = 16), mixed syndrome (truncal fat accumulation and face or limb lipoatrophy) (n = 30) or pure truncal fat accumulation (In = 5). Because of the small number, the latter group was not analyzed statistically. No differences were found among patients with lipoatrophy, mixed syndrome, or no lipodystrophy, in terms of gender, CD4 count, and HIV RNA plasma load at time of HAART initiation, nor in response to treatment. Patients with a mixed syndrome were older. Patients with lipoatrophy had longer duration of HIV disease, pre-HAART exposure to nucleoside analog therapy, and HAART. Baseline and pre-HAART fasting triglyceride levels were higher in patients who developed lipoatrophy, whereas weight and fasting cholesterol were higher in patients who developed a mixed syndrome. After 12 and 24 months on HAART, triglycerides and cholesterol rose significantly in all patients, independently of lipodystrophy, whereas these parameters were not increased during nucleoside analog therapy. Conclusions: Nucleoside analog exposure appears as a risk factor for lipoatrophy. Age and nutritional status (reflected by baseline weight, triglycerides and cholesterol) may influence the evolution to lipoatrophy or a mixed syndrome. Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [41] Low Levels of Adherence to Antiretroviral Therapy in HIV-1-Infected Women with Menstrual Disorders
    Fumaz, Carmina R.
    Munoz-Moreno, Jose A.
    Jose Ferrer, Maria
    Negredo, Eugenia
    Perez-Alvarez, Nuria
    Tarrats, Antoni
    Clotet, Bonaventura
    AIDS PATIENT CARE AND STDS, 2009, 23 (06) : 463 - 468
  • [42] Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy
    Perez-Valero, Ignacio
    Gonzalez-Baeza, Alicia
    Estebanez, Miriam
    Montes-Ramirez, Maria L.
    Bayon, Carmen
    Pulido, Federico
    Bernardino, Jose I.
    Zamora, Francisco X.
    Monge, Susana
    Gaya, Francisco
    Lagarde, Maria
    Rubio, Rafael
    Hernando, Asuncion
    Arnalich, Francisco
    Arribas, Jose R.
    PLOS ONE, 2013, 8 (07):
  • [43] Poor functional immune recovery in aged HIV-1-infected patients following successfully treatment with antiretroviral therapy
    Kasahara, Taissa M.
    Hygino, Joana
    Andrade, Regis M.
    Monteiro, Clarice
    Sacramento, Priscila M.
    Andrade, Arnaldo F. B.
    Bento, Cleonice A. M.
    HUMAN IMMUNOLOGY, 2015, 76 (10) : 701 - 710
  • [44] Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study
    Hung, CC
    Hsiao, CF
    Wang, JL
    Chen, MY
    Hsieh, ZM
    Sheng, WH
    Chang, SC
    INTERNATIONAL JOURNAL OF STD & AIDS, 2005, 16 (10) : 673 - 676
  • [45] Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy
    van Leth, F
    Wit, FWNM
    Reiss, P
    Schattenkerk, JKME
    van der Ende, ME
    Schneider, MME
    Mulder, JW
    Frissen, PHJ
    deWolf, F
    Lange, JMA
    HIV MEDICINE, 2004, 5 (02) : 74 - 81
  • [46] Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy
    Risa, KJ
    Nepon, L
    Justis, JC
    Panwalker, A
    Berman, SM
    Cinti, S
    Wagener, MM
    Singh, N
    INTERNATIONAL JOURNAL OF STD & AIDS, 2002, 13 (10) : 706 - 713
  • [47] Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy
    Mallon, PWG
    Miller, J
    Cooper, DA
    Carr, A
    AIDS, 2003, 17 (07) : 971 - 979
  • [48] Role of protease inhibitor 9 in survival and replication of Mycobacterium tuberculosis in mononuclear phagocytes from HIV-1-infected patients
    Toossi, Zahra
    Wu, Mianda
    Liu, Shigou
    Hirsch, Christina S.
    Walrath, Jessica
    van Ham, Marieke
    Silver, Richard F.
    AIDS, 2014, 28 (05) : 679 - 687
  • [49] Tipranavir:: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients
    de Mendoza, Carmen
    Morello, Judit
    Garcia-Gasco, Pilar
    Rodriguez-Novoa, Sonia
    Soriano, Vincent
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (06) : 839 - 850
  • [50] Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy
    Ndumbi, P.
    Gillis, J.
    Raboud, J.
    Cooper, C.
    Hogg, R. S.
    Montaner, J. S. G.
    Burchell, A. N.
    Loutfy, M. R.
    Machouf, N.
    Klein, M. B.
    Tsoukas, C.
    HIV MEDICINE, 2014, 15 (03) : 153 - 164